Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/14770
Título
Targeting the MAPK Pathway in KRAS-Driven Tumors.
Autor(es)
Drosten, Matthias CNIO | Barbacid, Mariano CNIO
Fecha de publicación
2020-04-13
Cita
Cancer Cell . 2020;37(4):543-550.
Idioma
Inglés
Tipo de documento
journal article
Resumen
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we review recent efforts to validate individual components of the mitogen-activated protein kinase (MAPK) pathway as targets to treat KRAS-mutant cancers by comparing genetic information derived from experimental mouse models of KRAS-driven lung and pancreatic tumors with the outcome of selective MAPK inhibitors in clinical trials. We also review the potential of RAF1 as a key target to block KRAS-mutant cancers.
MESH
Molecular Targeted Therapy | Mutation | Humans | Mitogen-Activated Protein Kinases | Neoplasms | Protein Kinase Inhibitors | Proto-Oncogene Proteins p21(ras)
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
- Nombre:
- targetingthemapkpathway_2020.pdf
- Tamaño:
- 955.5Kb
- Formato:
- Descripción:
- Artículo principal